Brian R Lindman1, Alan Zajarias1, Hersh S Maniar1, D Craig Miller2, Rakesh M Suri3, Suzanne V Arnold4, John Webb5, Lars G Svensson6, Susheel Kodali7, Ke Xu8, Girma M Ayele8, Fay Lin9, Shing-Chiu Wong9, Vasilis Babaliaros10, Vinod H Thourani10, Pamela S Douglas11, Scott Lim12, Martin B Leon7, Michael J Mack13. 1. Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri, USA. 2. Stanford University School of Medicine, Stanford, California, USA. 3. Mayo Clinic, Rochester, Minnesota, USA. 4. Mid-America Heart Institute, Kansas City, Missouri, USA. 5. St Paul's Hospital, Vancouver, British Columbia, Canada. 6. Cleveland Clinic Foundation, Cleveland, Ohio, USA. 7. Cardiovascular Research Foundation, New York, New York, USA Columbia University Medical Center/New York Presbyterian Hospital, New York, New York, USA. 8. Cardiovascular Research Foundation, New York, New York, USA. 9. New York Presbyterian Hospital, New York, New York, USA. 10. Emory University School of Medicine, Atlanta, Georgia, USA. 11. Duke University School of Medicine, Durham, North Carolina, USA. 12. University of Virginia School of Medicine, Charlottesville, Virginia, USA. 13. Baylor Scott and White Health, Plano, Texas, USA.
Abstract
OBJECTIVE: Pulmonary hypertension (PH) is associated with increased mortality after surgical or transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS), and when the pulmonary artery pressure is particularly elevated, there may be questions about the clinical benefit of TAVR. We aimed to identify clinical and haemodynamic factors associated with increased mortality after TAVR among those with moderate/severe PH. METHODS: Among patients with symptomatic AS at high or prohibitive surgical risk receiving TAVR in the Placement of Aortic Transcatheter Valves (PARTNER) I randomised trial or registry, 2180 patients with an invasive measurement of mean pulmonary artery pressure (mPAP) recorded were included, and moderate/severe PH was defined as an mPAP ≥35 mm Hg. RESULTS:Increasing severity of PH was associated with progressively worse 1-year all-cause mortality: none (n=785, 18.6%), mild (n=838, 22.7%) and moderate/severe (n=557, 25.0%) (p=0.01). The increased hazard of mortality associated with moderate/severe PH was observed in females, but not males (interaction p=0.03). In adjusted analyses, females with moderate/severe PH had an increased hazard of death at 1 year compared with females without PH (adjusted HR 2.14, 95% CI 1.44 to 3.18), whereas those with mild PH did not. Among males, there was no increased hazard of death associated with any severity of PH. In a multivariable Cox model of patients with moderate/severe PH, oxygen-dependent lung disease, inability to perform a 6 min walk, impaired renal function and lower aortic valve mean gradient were independently associated with increased 1-year mortality (p<0.05 for all), whereas several haemodynamic indices were not. A risk score, including these factors, was able to identify patients with a 15% vs 59% 1-year mortality. CONCLUSIONS: The relationship between moderate/severe PH and increased mortality after TAVR is altered by sex, and clinical factors appear to be more influential in stratifying risk than haemodynamic indices. These findings may have implications for the evaluation of and treatment decisions for patients referred for TAVR with significant PH. TRIAL REGISTRATION: NCT00530894. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
OBJECTIVE:Pulmonary hypertension (PH) is associated with increased mortality after surgical or transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS), and when the pulmonary artery pressure is particularly elevated, there may be questions about the clinical benefit of TAVR. We aimed to identify clinical and haemodynamic factors associated with increased mortality after TAVR among those with moderate/severe PH. METHODS: Among patients with symptomatic AS at high or prohibitive surgical risk receiving TAVR in the Placement of Aortic Transcatheter Valves (PARTNER) I randomised trial or registry, 2180 patients with an invasive measurement of mean pulmonary artery pressure (mPAP) recorded were included, and moderate/severe PH was defined as an mPAP ≥35 mm Hg. RESULTS: Increasing severity of PH was associated with progressively worse 1-year all-cause mortality: none (n=785, 18.6%), mild (n=838, 22.7%) and moderate/severe (n=557, 25.0%) (p=0.01). The increased hazard of mortality associated with moderate/severe PH was observed in females, but not males (interaction p=0.03). In adjusted analyses, females with moderate/severe PH had an increased hazard of death at 1 year compared with females without PH (adjusted HR 2.14, 95% CI 1.44 to 3.18), whereas those with mild PH did not. Among males, there was no increased hazard of death associated with any severity of PH. In a multivariable Cox model of patients with moderate/severe PH, oxygen-dependent lung disease, inability to perform a 6 min walk, impaired renal function and lower aortic valve mean gradient were independently associated with increased 1-year mortality (p<0.05 for all), whereas several haemodynamic indices were not. A risk score, including these factors, was able to identify patients with a 15% vs 59% 1-year mortality. CONCLUSIONS: The relationship between moderate/severe PH and increased mortality after TAVR is altered by sex, and clinical factors appear to be more influential in stratifying risk than haemodynamic indices. These findings may have implications for the evaluation of and treatment decisions for patients referred for TAVR with significant PH. TRIAL REGISTRATION: NCT00530894. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: P Faggiano; F Antonini-Canterin; F Ribichini; A D'Aloia; V Ferrero; E Cervesato; D Pavan; C Burelli; G Nicolosi Journal: Am J Cardiol Date: 2000-01-15 Impact factor: 2.778
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Srijoy Mahapatra; Rick A Nishimura; Paul Sorajja; Stephen Cha; Michael D McGoon Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Corrado Tamburino; Davide Capodanno; Angelo Ramondo; Anna Sonia Petronio; Federica Ettori; Gennaro Santoro; Silvio Klugmann; Francesco Bedogni; Francesco Maisano; Antonio Marzocchi; Arnaldo Poli; David Antoniucci; Massimo Napodano; Marco De Carlo; Claudia Fiorina; Gian Paolo Ussia Journal: Circulation Date: 2011-01-10 Impact factor: 29.690
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: Josep Rodés-Cabau; John G Webb; Anson Cheung; Jian Ye; Eric Dumont; Christopher M Feindel; Mark Osten; Madhu K Natarajan; James L Velianou; Giuseppe Martucci; Benoît DeVarennes; Robert Chisholm; Mark D Peterson; Samuel V Lichtenstein; Fabian Nietlispach; Daniel Doyle; Robert DeLarochellière; Kevin Teoh; Victor Chu; Adrian Dancea; Kevin Lachapelle; Asim Cheema; David Latter; Eric Horlick Journal: J Am Coll Cardiol Date: 2010-01-22 Impact factor: 24.094
Authors: Marius M Hoeper; Joan Albert Barberà; Richard N Channick; Paul M Hassoun; Irene M Lang; Alessandra Manes; Fernando J Martinez; Robert Naeije; Horst Olschewski; Joanna Pepke-Zaba; Margaret M Redfield; Ivan M Robbins; Rogério Souza; Adam Torbicki; Michael McGoon Journal: J Am Coll Cardiol Date: 2009-06-30 Impact factor: 24.094
Authors: Jacqueline T DesJardin; Joanna Chikwe; Rebecca T Hahn; Judy W Hung; Francesca N Delling Journal: Circ Res Date: 2022-02-17 Impact factor: 17.367
Authors: Ahmad Masri; Islam Abdelkarim; Michael S Sharbaugh; Andrew D Althouse; Jeffrey Xu; Wei Han; Stephen Y Chan; William E Katz; Frederick W Crock; Matthew E Harinstein; Dustin E Kliner; Forozan Navid; Joon S Lee; Thomas G Gleason; John T Schindler; João L Cavalcante Journal: Heart Date: 2017-09-29 Impact factor: 5.994
Authors: Anthony A Bavry; Seyed H Aalaei-Andabili; Ashkan Karimi; Ki Park; Calvin Y Choi; Eddie W Manning; Thomas M Beaver; Wade W Stinson Journal: Cardiol Ther Date: 2017-06-30
Authors: Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli Journal: Front Cardiovasc Med Date: 2018-05-23